324 related articles for article (PubMed ID: 25373709)
1. High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.
Chen Y; Xing P; Chen Y; Zou L; Zhang Y; Li F; Lu X
World J Surg Oncol; 2014 Nov; 12():328. PubMed ID: 25373709
[TBL] [Abstract][Full Text] [Related]
2. MiRNA-200a expression is inverse correlation with hepatocyte growth factor expression in stromal fibroblasts and its high expression predicts a good prognosis in patients with non-small cell lung cancer.
Chen Y; Du M; Wang J; Xing P; Zhang Y; Li F; Lu X
Oncotarget; 2016 Jul; 7(30):48432-48442. PubMed ID: 27374174
[TBL] [Abstract][Full Text] [Related]
3. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
[TBL] [Abstract][Full Text] [Related]
4. CD10 expression in epithelial and stromal cells of non-small cell lung carcinoma (NSCLC): a clinic and pathologic correlation.
Gürel D; Kargı A; Karaman I; Onen A; Unlü M
Pathol Oncol Res; 2012 Apr; 18(2):153-60. PubMed ID: 21681600
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.
Zhou L; Yu L; Wu S; Feng Z; Song W; Gong X
World J Surg Oncol; 2015 Aug; 13():234. PubMed ID: 26231404
[TBL] [Abstract][Full Text] [Related]
7. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of COX-2 in non-small cell lung cancer: a comprehensive compartment-specific evaluation of tumor and stromal cell expression.
Mattsson JS; Bergman B; Grinberg M; Edlund K; Marincevic M; Jirström K; Pontén F; Hengstler JG; Rahnenführer J; Karlsson MG; Karlsson C; Helenius G; Botling J; Micke P; Gulyas M
Cancer Lett; 2015 Jan; 356(2 Pt B):837-45. PubMed ID: 25449785
[TBL] [Abstract][Full Text] [Related]
9. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
10. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014).
Grossi F; Spizzo R; Bordo D; Cacitti V; Valent F; Rossetto C; Follador A; Di Terlizzi S; Aita M; Morelli A; Fasola G; Consiglieri C; Ceschia T; Beltrami CA; Belvedere O
J Thorac Oncol; 2010 Sep; 5(9):1354-60. PubMed ID: 20631638
[TBL] [Abstract][Full Text] [Related]
11. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.
Dhillon T; Mauri FA; Bellezza G; Cagini L; Barbareschi M; North BV; Seckl MJ
J Thorac Oncol; 2010 Mar; 5(3):314-9. PubMed ID: 20093977
[TBL] [Abstract][Full Text] [Related]
13. Polycomb group oncogene RING1 is over-expressed in non-small cell lung cancer.
Zhou Y; Wan C; Liu Y; Lv L; Chen B; Ni R; Huang Y; Li Y; Zheng X; Yang D; Mao G; Xue Q
Pathol Oncol Res; 2014 Jul; 20(3):549-56. PubMed ID: 24414991
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC.
Oliemuller E; Peláez R; Garasa S; Pajares MJ; Agorreta J; Pío R; Montuenga LM; Teijeira A; Llanos S; Rouzaut A
Int J Cancer; 2013 May; 132(9):1986-95. PubMed ID: 23023514
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
Tsoukalas N; Aravantinou-Fatorou E; Tolia M; Giaginis C; Galanopoulos M; Kiakou M; Kostakis ID; Dana E; Vamvakaris I; Korogiannos A; Tsiambas E; Salemis N; Kyrgias G; Karameris A; Theocharis S
Anticancer Res; 2017 Apr; 37(4):1773-1778. PubMed ID: 28373440
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of IGF1R expression in non-small-cell lung cancer.
Nakagawa M; Uramoto H; Oka S; Chikaishi Y; Iwanami T; Shimokawa H; So T; Hanagiri T; Tanaka F
Clin Lung Cancer; 2012 Mar; 13(2):136-42. PubMed ID: 22133293
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
J Thorac Oncol; 2009 May; 4(5):578-85. PubMed ID: 19318994
[TBL] [Abstract][Full Text] [Related]
18. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
[TBL] [Abstract][Full Text] [Related]
19. Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer.
Urquhart G; Kerr KM; Nicolson M; Loo PS; Sharma R; Shrimali R; Petty RD
J Thorac Oncol; 2013 Dec; 8(12):1502-9. PubMed ID: 24389432
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base.
Osarogiagbon RU; Lin CC; Smeltzer MP; Jemal A
J Thorac Oncol; 2016 Jan; 11(1):e5-16. PubMed ID: 26762752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
